Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn’s Disease

The response to treatment with biologic drugs, in patients with Crohn’s disease, could be associated with changes in gut microbiota composition. The aim of our study was to analyse the modification of microbiota during adalimumab therapy in patients with Crohn’s disease. We performed a prospective s...

Descripción completa

Detalles Bibliográficos
Autores principales: Ribaldone, Davide Giuseppe, Caviglia, Gian Paolo, Abdulle, Amina, Pellicano, Rinaldo, Ditto, Maria Chiara, Morino, Mario, Fusaro, Enrico, Saracco, Giorgio Maria, Bugianesi, Elisabetta, Astegiano, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6832711/
https://www.ncbi.nlm.nih.gov/pubmed/31601034
http://dx.doi.org/10.3390/jcm8101646

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6832711/
https://www.ncbi.nlm.nih.gov/pubmed/31601034
http://dx.doi.org/10.3390/jcm8101646

Ejemplares similares